Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

NCT01462357 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1079

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL: Cervarix
BIOLOGICAL: Gardasil
DRUG: Placebo

Sponsor

GlaxoSmithKline